Results 151 to 160 of about 4,490 (182)

Entrectinib inhibits NLRP3 inflammasome and inflammatory diseases by directly targeting NEK7

Cell Reports Medicine, 2023
Xinru Zhou, Didi Liu
exaly  

In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK)

Investigational New Drugs, 2021
Stephen Fowler, Ken-Ichi Umehara, François Mercier   +2 more
exaly  

Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors

Investigational New Drugs, 2021
François Mercier, Nassim DJEBLI, Alex Phipps   +2 more
exaly  

Entrectinib

Reactions Weekly, 2016
openaire   +2 more sources

Development and application of a physiologically based pharmacokinetic model for entrectinib in rats and scale-up to humans: Route-dependent gut wall metabolism

Biomedicine and Pharmacotherapy, 2022
Jong Hyuk Byun, In-Soo Yoon, Dong-Gyun Han   +2 more
exaly  

Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications

ESMO Open, 2021
Jean-Yves Blay, M G Krebs, L Veronese
exaly  

Entrectinib

Reactions Weekly, 2018
openaire   +2 more sources

Exploring the binding characteristics of bovine serum albumin with tyrosine kinase inhibitor entrectinib: Multi-spectral analysis and theoretical calculation

Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2023
Jie-Hua Shi
exaly  

Population pharmacokinetic analysis of entrectinib in pediatric and adult patients with advanced/metastatic solid tumors: support of new drug application submission

Cancer Chemotherapy and Pharmacology, 2021
François Mercier, Nassim DJEBLI
exaly  

Entrectinib demonstrates prolonged efficacy in an adult case of radiation-refractory NTRK fusion glioblastoma

Neuro-Oncology Advances, 2022
Mustafa Kemal Başkaya, Dustin Deming, H Ian Robins   +2 more
exaly